BusinessIGC-AD1 Targeting Alzheimer’s Disease to be commercialized in early 2018 Through Medical DispensariesBy Nasdaq OMXOct 18, 2017, 12:01 PM UTC
BusinessIGC Prepares a Liquid Delivery Formulation of IGC-AD1 for Alzheimer’s Based on Novel In Vitro DataBy Nasdaq OMXOct 4, 2017, 12:00 PM UTC
BusinessIGC Builds Team Adding Industry Leader Dr. Chuanhai Cao, an expert on THC-Based Alzheimer’s Disease TreatmentsBy Nasdaq OMXAug 1, 2017, 12:42 PM UTC
